JAMA NetworkEvaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients with Surgically Resected Pancreatic Carcinoma with Node-Negative Disease After Neoadjuvant Therapy

In this multi-institutional study, AT significantly increased progression-free and overall survival in 430 patients with node-negative (N0) disease after NAT for localized pancreatic cancer (4.1 vs 2.1 and 5.3 vs 3.5 years, respectively). Patients who received neoadjuvant radiation had their overall survival benefit scaled back, while patients with perineural invasion saw an increase.